アイオワ州における転移性癌の臨床試験
アイオワ州内の拠点で、転移性癌に関する10件の研究が参加者を募集しています。
アイオワ州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
- 他4件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/05更新 · NCT05564377A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Des Moines
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- University of Iowa, Iowa City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- University of Iowa, Iowa City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Study of ASP1002 in Adults for Treatment of Solid Tumors
- University of Iowa Hospitals, Iowa City
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/23更新 · NCT05719558Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- University of Iowa Health Care, Iowa City
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/11更新 · NCT052833305-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
- University of Iowa Health Care, Iowa City
被験者募集中第1相
18歳〜99歳 · 全性別 · 2026/05/28更新 · NCT07404332A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- University of Iowa, Iowa City
被験者募集中第2/3相
全年齢 · 全性別 · 2026/04/02更新 · NCT06581406Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
- University of Iowa Hospitals & Clinics- Holden Comprehensive Cancer Center, Iowa City
被験者募集中第3相
18歳以上 · 全性別 · 2026/02/06更新 · NCT06127407SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Iowa City
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。